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Letter to the Editor
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the presence of different collaborating cytogenetic and molecular aberrations which are associated with treatment response. [1] [2] [3] Approximately 20% of the pediatric AML patients are classified as cytogenetically normal AML (CN-AML). 4 In the past decade, new prognostic relevant aberrations have been identified in CN-AML, such as NPM1, WT1, FLT3-ITD and CEBPA double mutations (CEBPAdm), which may improve future risk-group stratification. [5] [6] [7] [8] In addition to these mutations, we recently described recurrent cryptic NUP98/NSD1 and NUP98/KDM5A translocations in pediatric CN-AML. 9, 10 Still, some CN-AML samples have not been fully characterized.
Recently, Grossmann et al. discovered a somatic mutation in the BCL6 co-repressor (BCOR) gene in an adult CN-AML patient using whole-exome sequencing. 11 BCOR mutations were subsequently identified in 10/262 (~4%) adult CN-AML patients, unselected for cytogenetic abnormalities, and predicted a poor outcome. In addition, Li et al. discovered mutations in the BCL6 corepressor-like 1 (BCORL1) gene in 2/8 patients with secondary adult AML. 12 Further exploration identified somatic BCORL1 mutations in 10/173 (6%) of adult AML patients, of which 5 cases were diagnosed with secondary or treatment-related AML. In 8/10 patients these included nonsense, splice site, and frame-shift mutations, that were predicted to result in truncation of the protein, suggesting that BCORL1 is a tumor suppressor gene that may be inactivated by mutations. 13 In pediatric AML the role of BCOR and BCORL1 is unknown. Therefore we explored the frequency and impact of BCOR and BCORL1 mutations in pediatric AML in a molecularly well documented cohort of 230 pediatric AML patients.
Purified PCR products were directly sequenced. Sequence data were analyzed using None of the cell lines showed a mutation. In 4/83 patients a BCOR mutation (detailed in table 1b) was identified; 3 in exon 4 and 1 in exon 12. Three of these cases were CN-AML (3/48, 6.3%), and the fourth mutation was seen in a MNX1/ETV6 translocated AML. In only 1/83 patients a BCORL1 mutation was identified which resulted in a stop codon (table1b).
This CN-AML patient had an underlying xeroderma pigmentosum.
An additional 147 pediatric AML patients were screened for mutations in BCOR and BCORL1 exon 4, based on the occurrence of mutations in this exon; 136 cases were de novo AML, 11 cases were secondary AML, of which 6 cases were MDS which progressed to AML and 5 were secondary to earlier therapy because of another malignancy. Apart from mutation analyses, we studied BCOR and BCORL1 gene expression levels using RT-qPCR in 65 patients of the initial cohort, including all mutated cases. Expression levels were determined using a SYBRgreen (Finnzymes Inc, Woburn, MA, USA) Taqman assay and average cycle threshold (CT) values were compared to the reference gene GAPDH, using the comparative cycle time method. Expression levels of 2 BCOR-mutated cases seemed lower than the other pediatric AML cases, but the 4 mutated cases did not significantly deviate from the non-mutated pediatric AML patients (supplementary figure 1) . This is in accordance with findings in adult AML patients where both decreased and normal BCOR levels were observed in cases with BCOR mutations. 11 In adult AML BCORL1 mutations did not affect mRNA levels, similar to the finding of our single case (0.297% expression relative to GAPDH, mean in group (n=65) 0.275% range 0.049-1.358). 13, 15 In the adult CN-AML cohort, the presence of BCOR mutations conferred a poor outcome. In our cohort, the low frequency of mutations did not allow survival analysis.
Clinical outcome of the mutated cases is shown in table 1b. The presence of the nonsynonymous SNP in BCORL1, rs5932715, did not influence clinical outcome (5-yr pOS 57±9% vs 64±4%, p=0.4; 5-yr pEFS 49±9% vs 45±4, p=0.9).
In conclusion, in pediatric AML BCOR and BCORL1 mutations rarely occur. Consequently, the clinical relevance is difficult to determine.
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